Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
“This new patent signals Sermonix’s continued momentum toward the broader study of and potential use of lasofoxifene beyond that in the ESR1-mutated setting, including use in earlier lines of therapy in patients with wild-type (WT) ER,” said Dr. David Portman, Sermonix founder and chief executive officer. “There is great medical need for efficacious and well-tolerated new therapies for this large population of breast cancer patients with WT ER who recur in the adjuvant setting or progress in the advanced setting on aromatase inhibitors. We look forward to investigating lasofoxifene’s potential as an effective therapy option for all hormone-treatment resistant breast tumors.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
